Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-17. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
2 SO3 + RCH2OH → RCH2OSO2−O−SO3H RCH2OSO2−O−SO3H → RCH2OSO3H + SO3 Several million tons of fatty acid sulfates are produced in this way annually. The most common example is sodium dodecylsulfate (SDS) derived from lauryl alcohol.
==== Class actions ==== In August 2015, Fairfax Media and the ABC's Four Corners program reported on the employment practices of certain 7-Eleven franchisees in Australia. The investigation found that many 7-Eleven employees were being underpaid at rates of around A$10 to A$14 per hour before tax, well under the legally required minimum award rate of A$24.69 per hour. The Four Corners investigation into 7-Eleven won a Walkley Award in 2015. Franchisees underpaying their staff would typically maintain rosters and pay records that appeared to show the employee being paid the legally required rate; however, these records only included half of the hours the employee actually worked in a week. Employees were then paid on the basis of these records, resulting in them effectively being paid half the legally required rate. It was also reported that workers were often not paid loadings and penalty rates that they are legally entitled to, for working overtime hours, nights, weekends, and public holidays. After these reports came to light and received widespread attention, some employees had alleged to Fairfax Media that they had begun to be paid correctly through the 7-Eleven payroll system; however, they were then asked by the franchisee to pay back half their wages in cash. 7-Eleven subsequently announced they would fund an inquiry to investigate instances of wage fraud. The inquiry was conducted by an independent panel chaired by former Australian Competition & Consumer Commission chairman Allan Fels, and with the support of professional services firm Deloitte.
=== Food === Before being introduced into the aquarium trade, the dwarf, along with the snakeskin gourami was and still is a popular food fish in its native range. In Bangladesh it is known as "Kholisha" and "Khosti" in India and "Kungee" in Punjab as well as different linguistic variants within its range.
=== Inkjet printing === A promising physical technique is inkjet printing, which allows for conductive materials to be deposited in a precise and reproducible fashion onto paper. As a proof-of-concept, Ko et al. developed a paper-based electrical chip using a home office printer, an ink made of carbon nanotubes, and magazine paper. Similarly, silver nanoparticles were printed into microfluidic channels to sense changes in the permittivity of fluids, revealing information about concentration and mixing ratios. Research groups have found, however, that these nanoparticle containing inks can self-aggregate on the paper due to uneven drying, which leads to non-uniform coverage and non-linear responses. A promising physical technique is inkjet printing, which allows for conductive materials to be deposited in a precise and reproducible fashion onto paper. In this regards, the controlled growth of nanoparticles can help to improve conductivity and sensing performances. As the seeds clusters grow and interconnect inside of the paper fibers, there properties and structure of the final material can be controlled through the process and chemical conditions. A typical growth process conditions consist dissolved metal ions in a reductive chemical environment. Once the nanoparticles have grown, they can be functionalized with recognition biomolecules to increase the specificity and sensitivity of the microfluidic devices. Inkjet printing is compatible with a wide variety of materials.
Sources: en.wikipedia.org
== Chemical structure == Dinosterol is a C30 sterol characterized by four fused rings (three six-membered and one five-membered), seven methyl groups, an olefin in its side-chain, and a secondary alcohol. The double bond in the side chain is located at the 22 position, and dinosterol's methyl groups are at the 20, 23, 24 and 25 positions of the side chain. The structure of dinosterol is established as 4α,23,24-trimethyl-5α-cholest-22-en-3β-ol. Dinosterol contains an unusual pattern of side-chain alkylation with methyl groups at C-23 and C-24. This substitution motif was thought to be unique to dinoflagellate sterols, until Volkman et al. (1993) found a diatom belonging to the genus Navicula, which contains several 4-methyl sterols including dinosterol.
Lately Chair, Cwm Taf Morgannwg University Health Board. For services to the NHS and Mental Health Services in Wales. Gregory Elliot. Senior Officer, National Crime Agency. For services to Law Enforcement. Stuart John Ensor. National Chair, Royal Air Force Air Cadets. For voluntary service to Young People. John Neil Everitt. Chief Executive Officer, National Forest Company. For services to Conservation. David Farnsworth. Managing Director, City Bridge Foundation. For services to the Voluntary Sector in London. Dr. Oliver Robert Ford Davies. Actor. For services to Drama. Professor David Foskett, MBE. Lately Head of Hospitality, University of West London. For services to the Hospitality Industry and to Inclusivity. Mischa Kate Foxell. Deputy Director, Cabinet Office. For Public Service. Travis Dylan Frain. Campaigner. For services to Counter Extremism and to Victims of Terrorism. Janie Lorraine Frampton. For services to Equality for Women in Sport in the UK and Abroad. Rachel Gaisburgh-Watkyn. Managing Director, Tiny Box Company. For services to Sustainability, to Ethical Business Growth and to Exports. Anthony Gallagher. Chair, National Youth Sector Advisory Board. For services to Young People. Katie Gallagher. Director, Manchester Digital. For services to the Digital Technology Industry in the North-West. Mark Robert Timothy Garnier, MP. Member of Parliament for Wyre Forest. For Political and Public Service. Sandra Godley. For charitable service to the community in Coventry, West Midlands. Bruce Malcolm Gordon. Chair and Founder Member, Honorary Treasurers Forum.
=== Cryobank === Provides long-term sample storage in liquid nitrogen. Consists of two units: one for cell lines and hybridomas, and another for mouse genetic material. The facility has automated storage systems with backup power and remote monitoring of environmental conditions. Also supplies dry ice.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.